High-Volume Metastatic Prostate Cancer: Triplet Therapy at 74
High-volume disease squarely inside the ARASENS and PEACE-1 populations on paper — the actual question is whether a 74-year-old who still works full days on a construction site should get the same triplet those trials tested on a younger average patient.
D.W., a 74-year-old man, still works full days as a construction site supervisor, on his feet checking framing and grading most of a shift — a pace his two sons, who work under him, say he hasn't slowed from in years. He came in for a stubborn low back ache he'd attributed to the job itself, and a PSA drawn at his primary care visit came back at 340ng/mL. Staging imaging found diffuse osseous metastases — eleven lesions, several of them in the femora and humeri and so beyond the vertebral column and pelvis — which satisfies CHAARTED's high-volume definition of four or more bone lesions with at least one outside the axial skeleton, without needing the visceral-metastasis criterion at all. Biopsy of a rib lesion confirmed adenocarcinoma of prostatic origin. He has hypertension controlled on amlodipine and lisinopril, no diabetes, no cardiac history, and an ECOG performance status of 0 — he was, by his own description, on a ladder two days before this appointment.
High-volume disease is exactly the population in which adding docetaxel to ADT plus an androgen receptor pathway inhibitor has shown a real overall survival benefit over the doublet alone, but the two trials behind that claim are not identical on this point, and the difference matters for him: PEACE-1's abiraterone survival benefit was confined to its high-volume subgroup, while ARASENS was positive across the whole trial — hazard ratio 0.68 for death — with benefit holding in high-volume, high-risk, and low-risk groups alike. His high-volume disease sits inside the strongest evidence either trial produced. But both trials enrolled patients fit enough for six cycles of docetaxel, and while his performance status and daily activity argue he clears that bar functionally, ARASENS's median enrollment age sat several years younger than 74, and neither trial reports how its benefit holds up in the oldest quartile of participants specifically. The gap between "functionally fit" and "trial-representative age" is exactly what the team now has to decide how much weight to give. Observational registry data on docetaxel use in men over 75 do exist, though they are non-randomized, and consistently report higher rates of febrile neutropenia and early treatment discontinuation than the trials' own younger-skewing cohorts — a pattern that doesn't resolve his case directly but does mean the team is extrapolating past the edge of the strongest evidence, in degree rather than in kind.
At diagnosis, before ADT starts
This is high-volume disease and he's functionally excellent — I'd offer the triplet. ARASENS showed darolutamide added to ADT and docetaxel improved overall survival, hazard ratio 0.68, and PEACE-1 found the same shape of benefit adding abiraterone — though PEACE-1's was confined to high-volume disease while ARASENS held across volume subgroups. Either way, he's in the population where the evidence is strongest. He's on a construction site full days; I don't think his age alone should override what his function is telling us.
I'd slow down on that. Both of those trials' median enrollment age sits well under 74, and docetaxel's cumulative toxicity — myelosuppression, neuropathy, fatigue — climbs with age in ways that aren't fully captured by a performance status score taken at one visit. A doublet, ADT plus an ARPI, still has a real, well-established survival benefit over ADT alone without that chemotherapy exposure.
His job tells us he's strong today. It doesn't tell us how his marrow reserve or peripheral nerves will hold up through six cycles at 74, which is a different question than whether he can walk a job site.
I'd push back gently on treating age itself as the variable. ECOG 0 with sustained full-time physical labor is about as strong a functional signal as we get outside a formal geriatric assessment, and it's specific to him rather than a trial average. I'd offer the triplet with close monitoring — dose modification thresholds set in advance, not withheld preemptively — rather than let a birth year override what his own body is actually doing.
Agreed: triplet therapy — leuprolide, darolutamide, and docetaxel — started with explicit dose-modification thresholds (specific neuropathy grade, absolute neutrophil count checkpoints) defined before cycle one rather than decided reactively.
Not agreed, and named directly rather than smoothed over: how much weight his chronological age should carry going forward if early cycles are well tolerated.
The geriatric oncologist's position was that continued vigilance for delayed, cumulative toxicity is warranted regardless of how the first one or two cycles go, since age-related marrow and neurologic reserve can decline independent of early tolerance. The treating oncologist's view was that early tolerance should meaningfully shift the team's own threshold for concern, not just its dosing decisions. Both agreed to reassess formally at cycle three rather than resolve the disagreement now.